Best of ASCO - 2014 Annual Meeting

 

Welcome

Leukemia/Lymphoma

Pediatric Oncology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Association of regulatory- and helper-T- cells with inferior survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

Holger N. Lode

10530

COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.

Kimberly P. Dunsmore

10500

Effect of SLCO polymorphisms on high-dose methotrexate clearance in pediatric oncology patients.

Rachael R Schulte

e22503

Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children’s Oncology Group report.

Kelly D. Getz

10501

Evaluation of pegaspargase (PEG-ASP) adverse events among adolescents and young adults (AYAs) and younger patients with lymphoid malignancies (LM) at the Children’s Hospital of Eastern Ontario (CHEO).

Nicole Mathies

10531

Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California.

Elysia Marie Alvarez

10502

Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.

Yana Pikman

10518

Mifamutide treatment plus chemotherapy results in pediatric osteosarcoma patients in Ankara University Medical School Department of Pediatric Oncology: A single center experience.

Nurdan Tacyildiz

e22500

Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.

Thomas Alexander

TPS10575

Prevalence of high risk acute lymphoblastic leukemia (ALL) in Mexico, a possible explanation for outcome disparities.

Leonardo Verduzco-Rodriguez

e22501

The association between atopy and Hodgkin’s lymphoma in teenagers and young adults: A UK nationwide case control study.

Meena Rafiq

10526

The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays?

Julia Thornton Snider

10529